Despite the Trump administration's efforts to dismantle many initiatives from the Biden administration, the Medicare Drug Price Negotiation Program remains largely intact. This program, part of the Inflation Reduction Act, allows the government to negotiate prices for high-cost Medicare Part D drugs. While the administration has indicated a commitment to lower drug prices, concerns have arisen among Democratic senators about potential changes that could weaken the program's effectiveness. The Centers for Medicare and Medicaid Services (CMS) plans to solicit stakeholder input for improving the program but possesses significant rulemaking abilities that could alter its structure.
The Trump administration expresses commitment to lowering drug costs but may alter the negotiation program, concerning Democratic senators wary of undermining price agreements.
The Medicare Drug Price Negotiation Program, established under the IRA, allows the government to negotiate prices, aiming for direct reduction of medical expenses.
Collection
[
|
...
]